Clinicians battle insurance formularies, using evidence, step-therapy strategy, and two‑week outcome tracking to secure affordable psychiatric meds.
Clinicians navigate insurance formularies, prior authorizations, and step therapy—using 14‑day check-ins and PHQ‑9 data to win better meds.
Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.
Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.
How health systems break silos with multidisciplinary, patient-centered teams to improve CRM outcomes through coordinated, holistic care.
Clinicians weigh antipsychotic choices with patients, tracking labs and side effects, while navigating insurance and brand-vs-generic variability.
Experts reveal how stigma, misdiagnosis, and cost barriers delay depression, bipolar, and schizophrenia care—and what breaks the crisis cycle.
How combined therapies and proactive, team-based CRM care cut costs, streamline meds, and improve heart, kidney, and metabolic outcomes.
The panelists examined how the scarcity of mental health specialists creates a cascading effect on care capacity, where patients who do not respond to initial primary care treatment face an increasingly narrow pool of expert clinicians equipped to manage complex, refractory cases.
Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.
New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.
Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.
Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.
The expert dermatologist examined how patient-specific factors drive JAK inhibitor selection, with baricitinib favored for patients who prioritize an established long-term safety record, ritlecitinib preferred for adolescents aged 12 to 17 and patients with baseline dyslipidemia, and deuruxolitinib reserved for those seeking faster and more robust hair regrowth or who have not responded adequately to another JAK inhibitor.
Dr. Mostaghimi discussed the clinical trial data for deuruxolitinib, a JAK1/2 inhibitor dosed at 8 mg twice daily, which demonstrated a faster onset of action compared with baricitinib and ritlecitinib — achieving mid-30% Scalp Area and Hair Loss Tool (SALT) score less than 20 response rates at 24 weeks, approximately 3 months earlier than baricitinib at 36 weeks.
The panelist examined the pivotal trial design for baricitinib, which enrolled patients with severe AA — defined as a Scalp Area and Hair Loss Tool (SALT) score greater than 50 — and demonstrated that approximately 30% of patients achieved a SALT score below 20 at 36 weeks on the 4 mg dose, with the 2 mg dose performing substantially lower.
Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA.
The expert clinician examined the multidisciplinary approach to alopecia areata care, with the board-certified dermatologist serving as the central coordinator, supported by pediatricians and family practice providers for early recognition and timely referral, dermatopathologists for cases requiring biopsy, and specialists in endocrinology, rheumatology, and psychiatry or psychology for management of associated comorbidities and psychosocial needs.
The panelist discussed the SALT scoring system, which divides the scalp into four regions — the frontal parietal scalp, bilateral preauricular and postauricular scalp, and posterior scalp — and evaluates the percentage of hair loss in each area to produce a composite score ranging from 0 to 100, with a score below 20 serving as the primary efficacy benchmark in JAK inhibitor clinical trials.
The panelist examined the wide-ranging burden of alopecia areata on patients and their families, including the challenges of accessing specialist care, navigating prior authorization processes, and the financial strain faced by uninsured or underinsured patients who cannot access the three FDA-approved Janus kinase (JAK) inhibitors now available for this condition.
Dr. Amy McMichael highlighted the clinical presentation of alopecia areata, describing the characteristic patchy, round hair loss that can progress to more extensive forms including ophiasis, alopecia totalis, and alopecia universalis, with associated symptoms such as burning, stinging, conjunctivitis, and worsening allergic reactions from loss of eyelash and nasal hairs.
The panelists highlighted how stigma, misdiagnosis, and the concentration of mental health care in primary care settings collectively contribute to significant delays in patients receiving appropriate psychiatric treatment for MDD, bipolar depression, and schizophrenia.
Learn why CKD often goes undiagnosed in type 2 diabetes and how UACR screening plus obesity therapies can cut cardiovascular risk.
Uncover hidden CKD in type 2 diabetes: boost UACR screening, close diagnosis-to-treatment gaps, and navigate modern obesity therapies.
Factor XIa inhibitors emerge as safer stroke prevention, cutting harmful clots without excess bleeding—see which oral and IV drugs reach phase 3.
Learn how anticoagulants, antiplatelets, and atrial appendage closure prevent repeat ischemic stroke—and why early follow-up boosts adherence.
How awareness, screening, and team-based care help catch chronic kidney disease early and cut heart risk with new protective medicines.
Learn how tailored meds, diet, exercise, and cholesterol control help prevent repeat ischemic stroke—while balancing bleeding risk and adherence.
Experts reveal gaps in stroke detection, follow‑up and prevention, plus a simple “MATH” guide to hemorrhagic causes and blood pressure goals.
